submit to the journals

Neurofibromatosis Neurosurgical Treatment and Follow-up

European Neurological Review, 2007;(2):14-16 DOI: http://doi.org/10.17925/ENR.2007.00.02.14

Neurofibromatosis Type I

Neurofibromatosis type I (NFI), also known as von Recklinghausen disease, is one of the most common inherited diseases in humans. Its incidence is one per 3,500–4,000 live births and it affects both sexes equally. NFI is an autosomal-dominant disorder and is the result of a mutation of a gene mapped to chromosome 17, which is the NFI gene.1,2 The product of the gene is a protein called neurofibromin, a GTPase-activating protein (GAP) that helps to maintain the protooncogene Ras in an inactive form. NFI is characterised by 100% penetrance but varying expressivity.

The diagnostic criteria for NFI have been formulated by the National Institutes of Health (NIH) Consensus Development Conference on NF,3 and include six or more café-au-lait macules (CALM), two or more neurofibromas of any type or one or more pleximorm neurofibroma, two or more Lisch nodules, distinct osseous lesions and a first-degree relative with NFI. If two or more of these signs are present, the diagnosis is NFI. Although direct sequencing could be used to detect the causative mutation for individuals who meet these diagnostic criteria for NFI, molecular testing is generally not necessary.

Patients with NFI manifest clinically with cutaneous, ophthalmological, musculoskeletal and/or neurological symptoms.4,5 The cutaneous and ocular manifestations are the most common and typically are CALM, axillary freckling and Lisch nodules. CALM are apparent in 99% of patients and are usually present at birth. Musculoskeletal abnormalities include bone abnormalities, such as skeletal dysplasia (particularly sphenoid wing dysplasia), scoliosis and tibial pseudarthrosis. The neurological manifestations of NFI are variable and may be due to brain, spine or peripheral nerve tumours, epilepsy, macrocephaly, hydrocephalus, meningoceles and/or peripheral neuropathy.

Neurofibromas in NFI manifest as cutaneous neurofibromas, subcutaneous neurofibromas, nodular plexiform neurofibromas and diffuse plexiform neurofibromas.6 In contrast with cutaneous neurofibromas, plexiform neurofibromas may undergo malignant transformation. Both NFI and NFII patients are at increased risk of developing intra-cranial tumours; however, the tumour types are quite different. Brain tumours that have a higher incidence in NFI patients than in the general population are gliomas, ependymosmas, meningiomas and primitive neuroectodermal tumours (PNETs). Gliomas are typically low-grade and involve the optic pathways, hypothalamus, cerebellum, brainstem and spinal cord.

References:
  1. Lee MJ, Stephenson DA, Recent developments in neurofibromatosis type 1, Curr Opin Neurol, 2007;20:135–41.
  2. Ward BA, Gutmann DH, Neurofibromatosis 1: from lab bench to clinic, Pediatr Neurol, 2005;32:221–8.
  3. Neurofibromatosis, Conference Statement, National Institutes of Health Consensus Development Conference, Arch Neurol, 1988; 45:575–8.
  4. Al-Otibi M, Rutka JT, Neurosurgical implications of neurofibromatosis Type I in children, Neurosurg Focus, 2006;20(1):E2.
  5. Yohay K, Neurofibromatosis types 1 and 2, Neurologist, 2006; 12:8693.
  6. Leonard JR, Ferner RE, Thomas N, Gutmann DH, Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1, J Neurol Neurosurg Psychiatry, 2007;78(12):1404–6.
  7. Thiagalingam S, Flaherty M, Billson F, et al., Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients, Ophthalmology, 2004;111:568–77.
  8. Packer RJ, Gutmann DH, Rubenstein A, et al., Plexiform neurofibromas in NF1: Toward biologic based therapy, Neurology, 2002;58:1461–70.
  9. Neff BA, Welling DB: Current concepts in the evaluation and treatment of neurofibromatosis type II. Otolaryngol Clin North Am, 2005;38:671–84.
  10. Samii M, Matthies C, Tatagiba M, Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2, Neurosurgery, 1997;40: 696–706.
  11. Baser ME, Gareth DR, Evans DG, Gutmann DH, Neurofibromatosis 2, Curr Opin Neurol, 2003;16:27–33.
  12. National Institutes of Health Consensus Development Conference: Statement on Acoustic Neuroma, Arch Neurol, 1994;51:201–7.
  13. Meng JJ, Lowrie DJ, Sun H, et al., Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin, J Neurosci Res, 2000;62:491–502.
  14. Bradley WD, Clinical manifestations of mutations in the neurofibromatosis Type 2 gene in vestibular schwannomas (acoustic neuromas), Laryngoscope, 1998;108:178–89.
  15. Evans DG, Baser ME, O`Reilly B, et al., Management of the patient and family with neurofibromatosis 2: a consensus conference statement, Br J Neurosur, 2005;19:5–12.
  16. Brackmann DE, Fayad JN, Slattery WH III, et al., Early proactive management of vestibular schwannomas in neurofibromatosis type 2, Neurosurg, 2001;49:274–80.
  17. Slattery WH III, Brackmann DE, Hitselberger W, Hearing preservation in neurofibromatosis type 2, Am J Otol, 1998;18: 638–43.
  18. Mathieu D, Kondziolka D, Flickinger JC, et al., Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates, Neurosurgery, 2007;60:460–68.
  19. Lenarz T, Moshrefi M, Matthies C, et al., Auditory brainstem implant: part I. Auditory performance and its evolution over time, Otol Neurotol, 2001;22:823–33.
  20. Lim H, Lenarz T, Joseph G, et al., Electrical stimulation of the midbrain for hearing restoration: Insight into the functional organization of the human central auditory system, J Neurosci, 2007;27(49):13541–51.